Abstract c-raf is a serine-threonine kinase and a downstream effector of ras signaling.
Introduction
c-raf is a serine-threonine kinase and plays an essential role in cell proliferation, differentiation, and apoptosis. It is a downstream effector of ras signaling and a member of the mitogenactivated protein kinase (MAPK) pathway [Ras-Raf-MAPK/ extracellular signal-regulated kinase (ERK) kinase-ERK]. The gene codes for three conserved domains [e.g., ras binding (CR1), activation/inactivation (CR2), and the kinase domain (CR3)] and interacts with an adapter of the 14-3-3 protein family (1) . On its dissociation from the 14-3-3 protein, c-raf interacts with ras and undergoes multiple phosphorylation. Next to c-raf, A-raf and B-raf are expressed in human tissues as well but differ in their ability to activate MAPK/ERK kinase (2) . Notably, targeted overexpression of c-raf to alveolar epithelium resulted in tumor development (3) and clinical trials are on the way to explore inhibition of the c-raf kinase in the combat of human malignancies (4) (5) (6) (7) (8) . Likely, the expression level of c-raf may be of critical importance in tumor development (3, 9, 10) , but recent experimental evidence links overexpression of wildtype B-raf to growth of malignant melanomas as well (11) .
In the past, we reported induction of c-raf gene expression in preneoplastic foci and tumor nodules of rat liver after feeding the nongenotoxic hepatocarcinogen Aroclor 1254 (12) . This mixture of chlorinated biphenyls contains isomers and congeners, some of which are high-affinity ligands of the aryl hydrocarbon receptor (AhR). Specifically, on ligand binding, AhR translocates to the nucleus and heterodimerizes with ARNT (heat shock -inducible factor 1h). After some modifications, this complex binds to recognition sequences, termed xenobiotic-responsive element (XRE) or dioxin-responsive element, and interacts with the basal transcriptional machinery to regulate expression of genes targeted by this factor such as CYP1A1 and others assigned to the Ah gene battery (13) . The mechanism resulting in c-raf transcriptional activation is unknown, as is the molecular organization of the rat c-raf promoter. Furthermore, it is uncertain whether AhR is capable of activating the c-raf promoter (12, 14) . This prompted our interest in exploring molecular interactions of AhR with the c-raf gene. Such interaction would enable cross-talk of the AhR with the RAS-ERK signaling pathway and may explain the exaggerated MAPK signaling observed in chemically induced neoplasms. Indeed, a recent example of an oncogenic activation of AhR was reported by Moennikes et al. (15) , where hepatocarcinogenesis was promoted in mice in an initiation-promotion cancer bioassay with N-nitrosodiethylamine as an initiator.
Here, we report our efforts in investigating the role of AhR in the control of c-raf gene transcription. Initially, we cloned from a genomic library the rat c-raf promoter. After DNA sequencing, we searched for recognition elements of the AhR by applying a genetic algorithm to predict AhR-binding sites (16) . We confirmed AhR-binding sites by electromobility shift assays (EMSA) and studied the effects of AhR activation on c-raf gene and protein expression. We additionally investigated the consequences of AhR antagonism by concomitant treatment of cultures of primary rat and human hepatocyte cultures with the AhR antagonist resveratrol and by measuring the transcriptional response of c-raf in hepatoma cell cultures with functional and devoid AhR. Because of similar biological functions, we aligned the sequences of the human and rat c-raf promoters and investigated the role of AhR in the transcriptional activation of these orthologues to enable cross-species comparison.
Overall, this study aimed for an improved understanding of the molecular organization of the rat c-raf promoter and its activation by AhR. 
Results

Induction of c-raf Gene Expression in Hepatoma and
H4IIE rat hepatoma cells after TCDD treatment. After normalizing the densitometric scan to the constitutively expressed glyceraldehyde-3-phosphate dehydrogenase gene (that means to the same amount of glyceraldehyde-3-phosphate dehydrogenase mRNA; see Fig. 1A ), a >10-fold increase in c-raf gene expression was observed with the Ah + -responsive clone, whereas the AhR-negative H4IIE cell line did not respond to this treatment. Furthermore, the Reuber and Zajdela cell lines were also responsive to treatment with TCDD, with c-raf mRNA expression being 6-and 11-fold induced, respectively (data not shown). We also investigated c-raf gene expression in cultures of human and rat hepatocytes and in rat liver after treatment with Aroclor 1254. Essentially, we observed a modest, on average 2-fold, mRNA induction of the human and rat c-raf gene (see Fig. 1B ), but expression of the coded protein was markedly induced (see Fig. 1C ). We also investigated the gene expression of the AhR repressor in cultures of primary hepatocytes but did not observe any regulation (data not shown). Therefore, we exclude a possible effect of AhR repressor in our study. Search for AhR-Binding Sites in the Human and Rat c-raf Promoters A comparison of the nucleotide sequences of the rat c-raf cDNA with those of the genomic DNA enabled us to align intron 1, exon 1, and the promoter sequences of the rat c-raf gene definitively, as shown in Fig. 2 .
Based on our findings, we were able to search for putative transcription start sites (tss) and therefore aligned our rat and the published human sequences of the c-raf gene (see Supplementary File 3). Our 333 additional 5 ¶-upstream nucleotides of the rat c-raf cDNA displayed a 74.5% homology with the exon 1 sequences of the human c-raf gene published by Beck et al. (17) . Noteworthy, our rat c-raf cDNA encompasses further 66 nucleotides upstream of the 5 ¶-upstream tss proposed by Beck et al. (17) for the human orthologue. It is of considerable interest that three ATG start codons were identified within exon 1, and we suggest alternative splicing to result in different cDNA lengths.
To determine AhR-binding sites in the human and rat c-raf promoter, we applied a genetic algorithm based on positional weight matrices as recently described by us (16) . Notably, the most widely used method for recognition of transcription factor binding sites is the application of positional weight matrices (18) . TRANSFAC is the largest collection of weight matrices for eukaryotic transcription factors (19) . In this database, three different weight matrices for AhR sites are stored (account numbers: M00139, M00235, and M00237). Here, we applied a novel weight matrix that was constructed based on 25 known, experimentally verified genomic AhR-binding sites (TRANS-FAC account number: M00778; id: V$AHR_Q5). All these matrices were used to search for AhR sites in genomic sequences of the c-raf gene. For this search, we used the MATCH algorithm calculating scores for the matches by applying the so-called information vector (16) . Based on the genomic sequence shown in Fig. 2 , we identified two binding sites within exon 1 and one binding site within the promoter close to the presumed tss of the rat c-raf gene. We also interrogated the published promoter sequence of the human c-raf gene (see Supplementary File 3) . One AhR-binding site was within exon 1, whereas another binding site was close to the tss. Three additional AhR-binding sites were upstream of the presumed polyadenylation signal (see Supplementary  File 3 ).
Confirmation of AhR Binding by EMSA
As shown in Fig. 3 , binding of nuclear proteins to RRP-1 (e.g., a site within the rat c-raf promoter) was increased after Aroclor 1254 treatment (lane 7), whereas binding of nuclear proteins to the exon 1 sites RRP-2 was less pronounced and, in the case of RRP-3, minimal. Competition with >100-fold excess of unlabeled wild-type probe completely shifted nuclear protein binding of AhR (lane 8), whereas no shift of the bands was possible with the mutated probes (lane 9).
As depicted in Fig. 3B (see lanes 6 and 9), treatment of rat hepatocyte cultures with the high-affinity ligand 3,3 ¶,4,4 ¶-tetrachlorobiphenyl (TCB) resulted in increased binding of the AhR/ARNT complex to predicted XRE sites, whereas treatment of human hepatocyte cultures with TCB was less clear and nuclear protein binding seemed to be only moderately increased (see Fig. 3C , lanes 6 and 7 or lanes 14 and 15, bearing in mind that the findings are based on this single donor). Notably, we confirm binding of AhR to predicted five and three XRE sites in the case of the human and rat c-raf promoters, respectively.
There seemed to be a relationship between location of the XRE site and DNA-binding activity. As shown in Fig. 3A and B, RRP-1 and HRP-4, both of which are localized in proximity to the tss (approximately À100 bp), displayed strong binding. With one donor, we observed strong binding with the HRP-2 probe, which contains a site >1 kbp upstream of the tss. This was not seen with other donors. In contrast, binding of nuclear proteins to other sites in the human and rat c-raf genes was moderate. Therefore, differences in the sequences of the flanking nucleotide position may also affect binding to the XRE.
To determine specificity of response, studies with the AhR antagonist resveratrol were carried out. Results are given in Fig.  3B and C, and binding of the AhR/ARNT was reduced in the presence of ligand (in this case TCB) and the AhR antagonist (e.g., see Fig. 3B , site RRP-1, lane 8, where binding was reduced by more than two thirds compared with lane 9). With human hepatocytes, the effects of treatment with the AhR antagonist were less pronounced.
Alignment of the Human and Rat c-raf Promoters
There are differences between both species in the number and location of XRE sites. Specifically, we observed three ATG start codons within exon 1. Our cDNA clone contained sequence information upstream of the transcriptional initiation site proposed by Beck et al. (17) . We suggest for the rat c-raf gene a tss at least 66 bases upstream of the human orthologue. There are important differences in the coding sequence of the orthologue c-raf gene, although 82% similarity was determined for exon 1 for both species. Note that the promoter sequences are grossly different, as shown in Supplementary File 3. Nonetheless, the molecular organization of these orthologue promoters seems to be similar (see TATA box, stop signal TTATTT, binding sites for AhR, etc.). Figure 4 depicts a summary of important features of the promoter of the rat and human c-raf gene (see Fig. 4 and Supplementary File 3).
Confirmation of AhR Activation after Treatment of Rat and Human Hepatocyte Cultures with Aroclor 1254 or TCB
As a positive control for AhR activation, we assayed for CYP1A1 gene and protein expression and ethoxyresorufin-Odeethylase enzyme activity. Essentially, treatment of human and rat hepatocyte cultures produced an up to 350-fold induction of CYP1A1 gene expression. Furthermore, CYP1A1 protein and enzyme activities were strongly induced as well (see Fig. 5 ), therefore providing further evidence for an activated AhR. We also studied the effects of the AhR antagonists 7-KC and AcSAL on CYP1A1 protein expression after AhR activation with the high-affinity ligand TCB. As shown in Fig. 5B , the CYP1A1 protein expression was markedly reduced when rat hepatocyte cultures were treated with the aforementioned AhR antagonists.
Discussion
We previously showed an induction of c-raf gene expression in rat liver tumor foci on treatment with the AhR agonist polychlorinated biphenyl. This prompted our interest in investigating the role of AhR in the transcriptional regulation of the c-raf proto-oncogene. We therefore aimed at identifying the molecular organization of the rat c-raf promoter. By applying a genetic algorithm, we were able to identify AhRbinding sites in genomic sequences of the human and rat c-raf genes. Predicted AhR-binding sites were confirmed by EMSAs and by studying c-raf gene expression on AhR ligand-mediated receptor activation. The role of AhR in the control of c-raf gene expression was further studied with polyclonal derivatives of AhR-responsive and AhR-negative rat hepatoma cell lines. This enabled insight into the molecular events leading to transcriptional regulation of the c-raf gene and thus to connect the aryl hydrocarbon to the MAPK signaling pathway. Furthermore, we used the competitive receptor antagonist resveratrol to ascertain the role of AhR in c-raf gene transcription. Results from cell cultures were confirmed by treating rats with Aroclor 1254 and/ or TCB (i.e., a high-affinity ligand for AhR).
Specifically, we were able to annotate f1,200 bases upstream of the coding sequence of the rat c-raf gene. Note that the rat and human c-raf genes are translated from exon 2 onwards (20, 21) . Exon 1 plays an important role in the regulation of this gene. Unlike Ishikawa et al. (20) , our cDNA clone contained an additional 333 bases of exon 1. By sequence alignment, we identified an additional 66 bases upstream of the putative transcription initiation site of the human c-raf promoter, as originally reported by Beck et al. (17) . These investigators proposed heterogeneous RNA start sites for the human c-raf gene, a finding similar to the rat c-raf gene as reported herein. Strikingly, the location of the three ATG start codons within exon 1 of the human and rat c-raf exon 1 is identical. Therefore, the assumed initiation site proposed by Beck et al. (17) may be questionable as denoted by these authors. We defined the start of exon 1 of the rat c-raf gene by alignment of the promoter sequence derived from the genomic clone and the rat c-raf cDNA clone (see Fig. 2 ).
Based on such alignment, the homology of nucleotide sequences of exon 1 of the human and rat c-raf genes was f82%. Unlike the promoter sequences of the human and rat c-raf genes, which we found to be similar by <50%, homology of the amino acid sequence for the human and rat c-raf protein is >98%. This comparison is based on DNA coding sequences and an algorithm originally described by Pearson et al. (22) .
Further important features of the rat c-raf promoter included annotation of the TATA box at nucleotide position À346 to À349, a termination stop signal TTATTTat À447 to À552 bp, in addition to an identification of further transcription factor binding sites (e.g., SP1, NF-1, AP-4, BARBIE 1 and 2, AP-1, nuclear factor-nB, and retinoid X receptor). These additional binding sites were confirmed by EMSA and are the subject of a separate report. Finally, we observed a polyadenylated tail at position À659 to À750 bp.
An important finding of our bioinformatic study was an identification of clusters of AhR-binding sites, which we found to be within exon 1 or within the promoter of the c-raf gene. All predicted AhR-binding sites were confirmed by EMSA and these sites contained mostly the GCGTGG motive. Therefore, the applied genetic algorithm enabled reliable prediction (see Supplementary File 3) . Based on the study of Bacsi et al. (23) , the ARNT heterodimeric partner of AhR contacts the thymine of the GCGTGG motive, which is considered to be an E-box halfsite. Notably, we observed differences in the binding activity between the various AhR-binding sites. Likely, variations in the flanking sequences around the AhR-binding sites and/or combinatorial interactions with other transcription factors will influence binding activity.
We further investigated the functional consequences of AhR activation on c-raf gene and protein expression. Notably, CYP1A1 served as a positive readout for AhR activation. We Indeed, AhR plays an essential role in receptor-mediated carcinogenesis (24) . Genetic studies and an application of gene targeting technologies provided valuable insight into AhR signaling pathways (25, 26) . Evidence obtained from studies with AhR-null mice provided clear evidence for the need of a functional receptor to induce carcinogenicity after treatment with benzo(a)pyrene (27) . Likewise, Anderson and colleagues (28) did gain-of-function studies and showed that a constitutively active AhR reduced the life span of transgenic mice with occurrence of tumors in the stomach. This further shows an oncogenic potential of the AhR.
Our study provides a functional link between AhR and the MAPK signaling pathways through targeted expression of c-raf. Constitutive activation of the RAS-ERK signaling pathway is common to numerous cancers and the functional link between AhR and c-raf points to a novel mechanism by which AhR agonists induce carcinogenesis by targeting the c-raf kinase. Nonetheless, AhR may function independently of its DNAbinding activity through a p38-mediated MAPK signaling pathway as reported for the transcriptional activation of the c-jun proto-oncogene (29).
FIGURE 5. CYP1A1 gene and protein expression and CYP1A1 enzyme activity in human and rat hepatocytes after treatment with Aroclor 1254 or TCB and/or the AhR antagonists 7-KC and AcSAL. A. CYP1A1 gene expression was determined by semiquantitative reverse transcription-PCR. B. CYP1A1 protein expression was determined by Western blot analysis using a human-and rat-specific antibody. C. CYP1A1 enzyme activity was determined as ethoxyresorufin-O -deethylase activity.
In conclusion, we propose a functional cross-talk between AhR ligand-mediated receptor activation and MAPK signaling through regulation of the c-raf proto-oncogene. We show a pivotal role of the AhR in the control of c-raf gene transcription. AhR ligand-mediated receptor activation of craf may provide a missing link between chemically induced carcinogenesis and MAPK kinase activation in neoplasms.
Materials and Methods
Isolation of cDNAs, Subcloning, and cDNA Sequencing
A rat liver cDNA library in the Lambda ZAP II vector (obtained from Stratagene) was plated at 50,000 plaqueforming units per 15-cm plate on XL1-Blue as host strain and screened for c-raf cDNA with 32 P-labeled, 310-bp BamHI-PstI fragment of the subclone R3AI of rat c-raf cDNA, as originally described by Ishikawa et al. (20) . The subclone was the kind gift of Dr. Sugimura's group (20) . DNA probes were labeled by nick translation (30) . Hybridization was done in 50% formamide at 42jC. Nine of 300,000 clones hybridized. Three further sequential rounds of amplification and screening were done according to the Stratagene and established protocols (31) . The cDNA clones isolated were subcloned into pBluescript KS À/+ (Stratagene). Restriction mapping was done by standard methods (31). The 5 ¶-upstream restriction fragment was subcloned in pBluescript KS À/+ and sequenced by the dideoxynucleotide chain termination method (32) using T7 Sequencing kit from Pharmacia LKB Biotechnology AB. All sequences were determined by analyzing both complementary strands using T3 and M13 primer and primers synthesized according to analyzed sequence data.
Isolation of Genomic DNA Clones, Subcloning, and DNA Sequencing A rat genomic library in the Lambda DASH II vector (obtained from Stratagene) was plated at 25,000 plaqueforming units per 15-cm plate on SRB as host strain and screened for c-raf genomic clones with 32 P-labeled, 260-bp Eco RI-Msp I 5 ¶-upstream fragment of the rat cDNA subclone, as described above. Twenty-three of 1.8 Â 10 6 clones hybridized. Three further sequential rounds of amplification and screening were done according to the Stratagene and established protocols (31) . Restriction mapping was done by standard methods (31). The 5 ¶-upstream, 3.2-kb EcoRI fragment was subcloned in pBluescript KS À/+ followed by large-scale isolation of the recombinant plasmid DNA and sequenced by the dideoxynucleotide chain termination method. We confirmed genomic sequences by capillary electrophoresis with the ABI 3100 Genetic Analyzer. Genomic clones were analyzed by double-strand direct sequencing using gene-specific primers, cycle sequencing using BigDye Terminator v3.1 kit, and injected to ABI 3100 Genetic Analyzer (Applied Biosystems). Sequences were analyzed using SeqMan (DNAStar) and found to be identical when compared with the dideoxynucleotide chain termination method.
Identification of a Rat c-raf cDNA Clone Encompassing the 5 ¶-Upstream Coding Region of Exon 1
The 2.5-kbp, MspI-PstI rat c-raf cDNA clone, subcloned into pGEM2 and termed pR3, was the kind gift of Dr. Sugimura (20) . This clone contained several restriction sites as depicted in Supplementary Fig. S1A . From this clone, we isolated a 310-bp BamHI-PstI fragment. This fragment was used to probe a recombinant rat liver cDNA library cloned into an EcoRI site of the Lambda ZAP II vector. Nine of 300,000 clones hybridized with the 310-bp BamHI-PstI probe. In the Supplementary Fig. S1BI files, a positive clone is depicted, which we obtained after three further sequential rounds of amplification and screening for hybridization products. The Southern blot analysis of a positive clone after digestion with EcoRI/PstI is shown in Supplementary Fig. S1BII , and the Southern blot hybridization with the 310-bp BamHI-PstI probe is depicted in Supplementary Fig. S1BIII . We therefore identified a rat liver cDNA clone containing primarily sequences of the 5 ¶-upstream region. This clone was sequenced by the dideoxynucleotide chain termination method and by capillary electrophoretic analysis. The sequence analysis of this cDNA subclone revealed additional 333 nucleotides of the 5 ¶-upstream region of the rat c-raf gene when compared with the originally published sequence of Ishikawa et al. (20) .
As we used a cDNA clone, the sequence information derived from this clone must be part of the coding sequence (e.g., downstream of the tss). We therefore isolated a rat c-raf cDNA clone that contained the complete sequence information of exon 1, as discussed in Discussion. Notably, the clone described by Ishikawa et al. (20) contained 15 nucleotides of exon 1 only.
Identification of a Rat c-raf Genomic Clone
A recombinant rat genomic library in the Lambda DASH II vector was screened using a 260-bp EcoRI-MspI fragment derived from our subclone. Twenty-three of 1.8 Â 10 6 clones hybridized with the 260-bp EcoRI-MspI probe. Supplementary Fig. S1C and D depict the experimental and theoretical restriction map of the genomic clone 85 in Lambda DASH II. A 3.2-kbp EcoRI-EcoRI fragment of the genomic clone 85 encompassing intron 1 sequences, exon 1 sequences, and f1,200 nucleotides 5 ¶-upstream of exon 1 of the rat c-raf gene was subcloned into the pBluescript KS +/À and sequenced by the dideoxynucleotide chain termination method. The genomic sequences were further analyzed by capillary electrophoresis with the ABI 3100 Genetic Analyzer. We found results to be identical using the different sequencing methods.
In Supplementary Fig. S2 , an example of a sequence gel is given. Note that we show the promoter region from À379 to À520 bp.
Search for Cognate Binding Sites in the Rat and Human c-raf Promoter
A novel genetic algorithm was applied to study composite structures of promoters of AhR-targeted genes, as recently reported by us (16) . 
Isolation of Nuclear Proteins
Nuclear extracts from rat liver and from human and rat hepatocyte cultures were prepared as described elsewhere (33, 34) .
Annealing of Synthetic Oligonucleotides and 32 P Labeling
Oligonucleotides representing high-affinity consensus AhRbinding sites (XRE) from the rat and human c-raf promoters were chosen as shown herein. For EMSA assays, we used mutated oligonucleotide probes as well to show specificity of nuclear protein binding. These probes are identified by the term mut (mutated).
Oligonucleotide probes to study AhR binding to XRE recognition sites in the promoter of the rat c-raf gene were Each oligonucleotide (1 nmol) was annealed in a buffer consisting of 20 mmol/L Tris (pH 7.6), 10 mmol/L MgCl 2 , and 50 mmol/L NaCl at 80jC for 10 min and then cooled slowly to room temperature overnight and stored at 4jC. Annealed oligonucleotides were diluted to 1:10 in Tris-EDTA (pH 8.0) buffer and labeled using [ 32 P]ATP (250 ACi, 3.000 Ci/mmol; Amersham) and T4 polynucleotide kinase (New England Biolabs). End-labeled probes were separated from unincorporated [
32 P]ATP with a Microspin G-25 column (Amersham) and eluted in a final volume of 100 AL.
Electromobility Shift Assay
EMSA was done as described previously (35) . Briefly, 5 Ag of nuclear extract and 10 5 cpm annealed oligonucleotide (see above) were incubated with the binding buffer consisting of 25 mmol/L HEPES (pH 7.6), 5 mmol/L MgCl 2 , 34 mmol/L KCl, 2 mmol/L DTT, 2 mmol/L Pefablock (Boehringer Mannheim), 0.5 AL aprotinin (2.2 mg/mL; Sigma), 50 ng poly(deoxyinosinic-deoxycytidylic acid), and 80 ng bovine serum albumin (PAA). The reaction was carried out for 20 min on ice. Free DNA and DNA/protein complexes were resolved on a 6% polyacrylamide gel. Competition studies were done by adding a 100-fold excess of unlabeled oligonucleotides to the reaction mixture. Gels were blotted to Whatman 3 MM paper, dried under vacuum, exposed to imaging screens (Imaging Screen-K, Bio-Rad) for 16 h at room temperature, and analyzed using a phosphorimaging system (Molecular Imager FX Pro Plus, Bio-Rad) and the Quantity One version 4.2.2 software (Bio-Rad). To ascertain specificity, EMSA was done with mutated probes as well (see above).
Primary Human and Rat Hepatocyte Cultures
Human and rat hepatocytes were isolated and cultured as described previously (36, 37) . For isolation of rat hepatocytes, a modified method originally described by Seglen (38) was used. Human hepatocytes were isolated from surgical material and approval was obtained from the ethics committee of the Medical School of Hannover.
Two million hepatocytes per dish were cultured on a collagen type I layer, and following 24 h in culture, nonadherent cells were removed and the second collagen layer was applied as originally described by Dunn et al. (39) . Hepatocytes were allowed to recover for 48 h and then used for further experiments. Solutions of Aroclor 1254 at a strength of 10 mg/mL were prepared in DMSO. These solutions were diluted as necessary with the cell culture medium to obtain doses of 20 Amol/L. The final concentration of DMSO in the cell culture medium was 0.5% (v/v). Cell cultures receiving 0.5% DMSO with the culture medium were used as controls. At the end of the study, cells and the collagen layer were immediately frozen at À80jC.
Activation and Inhibition of AhR by Aroclor 1254, TCB, Resveratrol, 7-KC, and AcSAL, Respectively Induction of gene expression was achieved with Aroclor 1254 (dissolved in DMSO). The rationale for dose selection is based on previous findings. For further details, see Borlak and Thum (40) . Aroclor 1254 concentrations (10 Amol/L) were optimal to induce gene expression. The DMSO concentration was 2.8 AL/mL medium, which accounts for <0.3% (v/v). The total medium per culture dish was 2 mL, and correspondingly, 5.6 AL DMSO was added to the cultures. There was no sign of cellular toxicity based on phase-contrast light microscopic examination and of clinical chemistry variables studied in the past (e.g., lactate dehydrogenase). Cultures of primary rat and human hepatocytes were treated with either 1, 10, or 20 Amol/L of Aroclor 1254 and 10 nmol/L TCB for 12, 24, or 48 h.
To inhibit AhR activation and DNA binding to XRE recognition sites, cells were treated with the AhR antagonist resveratrol (10 Amol/L), 7-KC (5 Amol/L), and AcSAL (400 Amol/L), respectively.
Cell Culture of AhR-Positive and AhR-Negative Cell Lines
The following cell lines were used: (a) Zajdela rat hepatoma cells (TZB 620076) were obtained from the German Cancer Research Centre and cultured in 90% MEM and 10% FCS as described previously (41) and (b) H4IIEC3 rat hepatoma cell line was cultured in 90% DMEM and 10% FCS as described previously (42, 43) .
Polyclonal variants of the above-named H4IIEC3 cell line were obtained after treatment of cells with dinitrophenole and benzo(a)pyrene and termed 5L + (AhR positive) as well as 5L
À (AhR negative) as described previously (44) .
H4IIEC3 rat hepatoma cells and polyclonal variants were the Treatment of Rat Hepatoma and AhR-Positive and AhRNegative Cell Lines with Aroclor 1254, Clophen A50, and TCDD Aroclor 1254 contains a complex mixture of >80 polychlorinated biphenyl isomers and congeners and was the kind gift of the U.S. Environmental Protection Agency. Clophen A50 also contains a complex mixture of >80 polychlorinated biphenyl isomers and congeners and was the kind gift of Dr. Wrabetz (Bayer AG, Wuppertal, Germany). Polychlorinated biphenyl mixtures were dissolved in DMSO and added to the culture medium at the desired concentration. Ethanolic stock solutions of TCDD were the gift of Prof. F. Wiebel and were diluted with DMSO to achieve the desired concentration. TCB was synthesized by Jürgen Borlak under the supervision of Dr. Larry Robertson (Graduate Center of Toxicology, Lexington, KY) and dissolved in DMSO. The identity and purity was confirmed by proton resonance spectroscopy as described previously (45) .
All cell lines were kept in a humidified incubator [air/CO 2 (95%/5%) at 37jC] and treated at f60% confluency. The Zajdela rat hepatoma cell line and the H4IIEC3 cells were treated with 50 Amol/L Clophen A50. The polyclonal descendants 5L + and 5L À cells were treated with 1 nmol/L TCDD for 2, 4, and 24 h.
Treatment of SD Rats with Aroclor 1254 or TCB SD rats were obtained from Charles River and kept in the animal house under standardized conditions with a 12-h light and dark cycle. Food and water were given ad libitum. SD rats (n = 4) were treated with either 100 mg/kg body weight Aroclor 1254 or 2 mg/kg TCB and killed after 72 h.
Northern and Southern Blot Analysis
For Northern blotting, 10 Ag of total cellular RNA were prepared as described by Chomczynski et al. (46) , denatured, separated electrophoretically on 1% agarose gels, blotted to nitrocellulose, and hybridized with 32 P-labeled probes as described earlier (14) .
For Southern blots, the genomic insert was isolated quantitatively from the large-scale preparation of the recombinant phage. Genomic DNA (1 Ag) was digested with appropriate restriction enzymes, fractionated by electrophoresis through 0.7% agarose gels, and processed by standard procedures (31) .
